About JANUS

Continue to JANUS Subgroup Data Visualization Tool  →

JANUS is a subgroup data visualization tool designed to provide tofacitinib (Xeljanz®) efficacy and safety outcomes from clinical trials (Rheumatoid Arthritis) by user selected * clinical trial patient subgroup(s) and displayed in real-time. This is not intended to be used for the management of any individual patient in a clinical setting. JANUS is also not to be used as research tool. JANUS is a post-hoc subgroup data visualization tool for educational purposes only.

Pfizer has existing data access request procedures for investigators interested in accessing Pfizer product clinical trial data for approved research projects. Please visit Pfizer’s data request portal for more information: Pfizer – Vivli 

*Clinical characteristics and efficacy and safety outcomes are pre-defined based on clinical trial information captured in the tofacitinib clinical development program. 

JANUS contains Pfizer-sponsored clinical trial data** including 10,875 tofacitinib-treated patients from the tofacitinib rheumatoid arthritis clinical development program. 

** Phase 1, Phase 2, Phase 3, Phase 3b/4 and long-term extension studies: 
A3921019, A3921024, A3921025, A3921032, A3921035, A3921039, A3921040, A3921041, A3921044, A3921045, A3921046, A3921064, A3921068, A3921069, A3921073, A3921109, A3921129, A3921130, A3921133, A3921152, A3921187, A3921192, A3921215, A3921237. 

For detail on how to use JANUS please go to the How To Use and FAQ pages.

Please read the full prescribing information here.

Continue to JANUS Subgroup Data Visualization Tool  →